The Filings Report

Glaukos Corporation

GKOSNYSECIK 1192448Healthcare / Medical Devicesfiscal year ends December51 quarters since 2014

Revenue, Q3 FY2026
$211M
+58.0% on Q3 FY2025
Net income
$2M
+112.4% on Q3 FY2025
Free cash flow
$36M
+411.2% on Q3 FY2025
Diluted EPS
$0.03
+110.7% on Q3 FY2025
Revenue, TTM
$690M
trailing four quarters
Net margin, TTM
-24.6%
net income −$170M
Free cash flow, TTM
$36M
$48M less $12M capex
Cash and equivalents
$162M
long-term debt —, Sep 30, 2026
Shares, 12-month change
+3.1%
59M shares, Sep 30, 2026
Buybacks, TTM
—
no yield
Dividends, TTM
—
no yield
Market value
$13.3B
at the close, buybacks

Latest quarter Q3 FY2026, filed October 28, 2026. Trailing figures sum the latest four quarters. Market values at the latest close, from a market data vendor.

In Q3 FY2026, the quarter ended September 30, 2026, Glaukos Corporation reported revenue of $211M, +58.0% on Q3 FY2025, and net income of $2M (+112.4%). Net income this quarter is driven by non-operating items: $1M of other income against $828K of operating income, so it reflects gains or losses outside the operations. Operating margin was 0.4%. Free cash flow, operating cash flow less capital expenditures, was $36M ($39M less $2M). Diluted earnings per share were $0.03.

Share price

Daily candlesticks from November 11, 2024 to November 6, 2026, with each earnings release marked; a release after the close marks the day it came out, so its reaction is the next candle. See this earnings season for every company’s reaction.

GKOS daily priceSplit-adjusted, US dollars; an earnings release
Nov 6, 2026O $221.51 · H $229.05 · L $219.06 · C $224.41 · +2.01% on the dayOver the range: +174.37%, Nov 7, 2025 to Nov 6, 2026
$70$119$168$217$266Nov 25Jan 26Apr 26Jun 26Aug 26Nov 26

The last 16 quarters

Q4 FY2022 to Q3 FY2026, through the filing of October 28, 2026.

Revenue and net incomeRevenueNet income
−$200M−$100M$0$100M$200M$300MQ4'22, Revenue: $71MQ4'22, Net income: −$31MQ4'22Q1'23, Revenue: $74MQ1'23, Net income: −$35MQ1'23Q2'23, Revenue: $80MQ2'23, Net income: −$33MQ2'23Q3'23, Revenue: $78MQ3'23, Net income: −$30MQ3'23Q4'23, Revenue: $82MQ4'23, Net income: −$37MQ4'23Q1'24, Revenue: $86MQ1'24, Net income: −$41MQ1'24Q2'24, Revenue: $96MQ2'24, Net income: −$51MQ2'24Q3'24, Revenue: $97MQ3'24, Net income: −$21MQ3'24Q4'24, Revenue: $105MQ4'24, Net income: −$34MQ4'24Q1'25, Revenue: $107MQ1'25, Net income: −$18MQ1'25Q2'25, Revenue: $124MQ2'25, Net income: −$20MQ2'25Q3'25, Revenue: $134MQ3'25, Net income: −$16MQ3'25Q4'25, Revenue: $143MQ4'25, Net income: −$134MQ4'25Q1'26, Revenue: $151MQ1'26, Net income: −$20MQ1'26Q2'26, Revenue: $186MQ2'26, Net income: −$18MQ2'26Q3'26, Revenue: $211MQ3'26, Net income: $2MQ3'26−$200M−$100M$0$100M$200M$300MQ4'22, Revenue: $71MQ4'22, Net income: −$31MQ4'22Q1'23, Revenue: $74MQ1'23, Net income: −$35MQ1'23Q2'23, Revenue: $80MQ2'23, Net income: −$33MQ2'23Q3'23, Revenue: $78MQ3'23, Net income: −$30MQ3'23Q4'23, Revenue: $82MQ4'23, Net income: −$37MQ4'23Q1'24, Revenue: $86MQ1'24, Net income: −$41MQ1'24Q2'24, Revenue: $96MQ2'24, Net income: −$51MQ2'24Q3'24, Revenue: $97MQ3'24, Net income: −$21MQ3'24Q4'24, Revenue: $105MQ4'24, Net income: −$34MQ4'24Q1'25, Revenue: $107MQ1'25, Net income: −$18MQ1'25Q2'25, Revenue: $124MQ2'25, Net income: −$20MQ2'25Q3'25, Revenue: $134MQ3'25, Net income: −$16MQ3'25Q4'25, Revenue: $143MQ4'25, Net income: −$134MQ4'25Q1'26, Revenue: $151MQ1'26, Net income: −$20MQ1'26Q2'26, Revenue: $186MQ2'26, Net income: −$18MQ2'26Q3'26, Revenue: $211MQ3'26, Net income: $2MQ3'26−$200M−$100M$0$100M$200M$300MQ4'22, Revenue: $71MQ4'22, Net income: −$31MQ1'23, Revenue: $74MQ1'23, Net income: −$35MQ1'23Q2'23, Revenue: $80MQ2'23, Net income: −$33MQ3'23, Revenue: $78MQ3'23, Net income: −$30MQ3'23Q4'23, Revenue: $82MQ4'23, Net income: −$37MQ1'24, Revenue: $86MQ1'24, Net income: −$41MQ1'24Q2'24, Revenue: $96MQ2'24, Net income: −$51MQ3'24, Revenue: $97MQ3'24, Net income: −$21MQ3'24Q4'24, Revenue: $105MQ4'24, Net income: −$34MQ1'25, Revenue: $107MQ1'25, Net income: −$18MQ1'25Q2'25, Revenue: $124MQ2'25, Net income: −$20MQ3'25, Revenue: $134MQ3'25, Net income: −$16MQ3'25Q4'25, Revenue: $143MQ4'25, Net income: −$134MQ1'26, Revenue: $151MQ1'26, Net income: −$20MQ1'26Q2'26, Revenue: $186MQ2'26, Net income: −$18MQ3'26, Revenue: $211MQ3'26, Net income: $2MQ3'26

Net income losses drawn in red.

Free cash flow
−$40M−$20M$0$20M$40MQ4'22, Free cash flow: −$12MQ4'22Q1'23, Free cash flow: −$38MQ1'23Q2'23, Free cash flow: −$14MQ2'23Q3'23, Free cash flow: −$12MQ3'23Q4'23, Free cash flow: −$15MQ4'23Q1'24, Free cash flow: −$35MQ1'24Q2'24, Free cash flow: −$21MQ2'24Q3'24, Free cash flow: −$11MQ3'24Q4'24, Free cash flow: −$1MQ4'24Q1'25, Free cash flow: −$20MQ1'25Q2'25, Free cash flow: $6MQ2'25Q3'25, Free cash flow: −$12MQ3'25Q4'25, Free cash flow: $4MQ4'25Q1'26, Free cash flow: −$16MQ1'26Q2'26, Free cash flow: $12MQ2'26Q3'26, Free cash flow: $36MQ3'26−$40M−$20M$0$20M$40MQ4'22, Free cash flow: −$12MQ4'22Q1'23, Free cash flow: −$38MQ1'23Q2'23, Free cash flow: −$14MQ2'23Q3'23, Free cash flow: −$12MQ3'23Q4'23, Free cash flow: −$15MQ4'23Q1'24, Free cash flow: −$35MQ1'24Q2'24, Free cash flow: −$21MQ2'24Q3'24, Free cash flow: −$11MQ3'24Q4'24, Free cash flow: −$1MQ4'24Q1'25, Free cash flow: −$20MQ1'25Q2'25, Free cash flow: $6MQ2'25Q3'25, Free cash flow: −$12MQ3'25Q4'25, Free cash flow: $4MQ4'25Q1'26, Free cash flow: −$16MQ1'26Q2'26, Free cash flow: $12MQ2'26Q3'26, Free cash flow: $36MQ3'26−$40M−$20M$0$20M$40MQ4'22, Free cash flow: −$12MQ1'23, Free cash flow: −$38MQ1'23Q2'23, Free cash flow: −$14MQ3'23, Free cash flow: −$12MQ3'23Q4'23, Free cash flow: −$15MQ1'24, Free cash flow: −$35MQ1'24Q2'24, Free cash flow: −$21MQ3'24, Free cash flow: −$11MQ3'24Q4'24, Free cash flow: −$1MQ1'25, Free cash flow: −$20MQ1'25Q2'25, Free cash flow: $6MQ3'25, Free cash flow: −$12MQ3'25Q4'25, Free cash flow: $4MQ1'26, Free cash flow: −$16MQ1'26Q2'26, Free cash flow: $12MQ3'26, Free cash flow: $36MQ3'26

Operating cash flow less capital expenditures; negative quarters in red.

Cash and equivalents against long-term debtCash and equivalentsLong-term debt
$0$50M$100M$150M$200MQ4'22, Cash and equivalents: $120MQ4'22Q1'23, Cash and equivalents: $76MQ1'23Q2'23, Cash and equivalents: $95MQ2'23Q3'23, Cash and equivalents: $109MQ3'23Q4'23, Cash and equivalents: $93MQ4'23Q1'24, Cash and equivalents: $42MQ1'24Q2'24, Cash and equivalents: $68MQ2'24Q3'24, Cash and equivalents: $100MQ3'24Q4'24, Cash and equivalents: $170MQ4'24Q1'25, Cash and equivalents: $114MQ1'25Q2'25, Cash and equivalents: $101MQ2'25Q3'25, Cash and equivalents: $98MQ3'25Q4'25, Cash and equivalents: $91MQ4'25Q1'26, Cash and equivalents: $104MQ1'26Q2'26, Cash and equivalents: $114MQ2'26Q3'26, Cash and equivalents: $162MQ3'26$0$50M$100M$150M$200MQ4'22, Cash and equivalents: $120MQ4'22Q1'23, Cash and equivalents: $76MQ1'23Q2'23, Cash and equivalents: $95MQ2'23Q3'23, Cash and equivalents: $109MQ3'23Q4'23, Cash and equivalents: $93MQ4'23Q1'24, Cash and equivalents: $42MQ1'24Q2'24, Cash and equivalents: $68MQ2'24Q3'24, Cash and equivalents: $100MQ3'24Q4'24, Cash and equivalents: $170MQ4'24Q1'25, Cash and equivalents: $114MQ1'25Q2'25, Cash and equivalents: $101MQ2'25Q3'25, Cash and equivalents: $98MQ3'25Q4'25, Cash and equivalents: $91MQ4'25Q1'26, Cash and equivalents: $104MQ1'26Q2'26, Cash and equivalents: $114MQ2'26Q3'26, Cash and equivalents: $162MQ3'26$0$50M$100M$150M$200MQ4'22, Cash and equivalents: $120MQ1'23, Cash and equivalents: $76MQ1'23Q2'23, Cash and equivalents: $95MQ3'23, Cash and equivalents: $109MQ3'23Q4'23, Cash and equivalents: $93MQ1'24, Cash and equivalents: $42MQ1'24Q2'24, Cash and equivalents: $68MQ3'24, Cash and equivalents: $100MQ3'24Q4'24, Cash and equivalents: $170MQ1'25, Cash and equivalents: $114MQ1'25Q2'25, Cash and equivalents: $101MQ3'25, Cash and equivalents: $98MQ3'25Q4'25, Cash and equivalents: $91MQ1'26, Cash and equivalents: $104MQ1'26Q2'26, Cash and equivalents: $114MQ3'26, Cash and equivalents: $162MQ3'26

Positions at each quarter end, as filed; short-term investments are not included.

Income statement

Last eight quarters, newest first, through Q3 FY2026 filed October 28, 2026.

Glaukos Corporation income statement, quarterly
Millions of dollarsQ3 FY2026ended Sep 30, 2026filed Oct 28, 2026Q2 FY2026ended Jun 30, 2026filed Jul 29, 2026Q1 FY2026ended Mar 31, 2026filed Apr 30, 2026Q4 FY2025ended Dec 31, 2025filed Feb 23, 2026Q3 FY2025ended Sep 30, 2025filed Oct 31, 2025Q2 FY2025ended Jun 30, 2025filed Aug 4, 2025Q1 FY2025ended Mar 31, 2025filed May 1, 2025Q4 FY2024ended Dec 31, 2024filed Feb 25, 2025YoYQ3 FY2026vs Q3 FY2025
Revenue211186151143134124107105+58.0%
Cost of revenue3134333229272429+8.1%
Gross profit180152117(2)105978277+71.8%
Research and development31———27———+15.2%
Selling, general and administrative131116939583837169+57.8%
Operating income1(17)(20)(140)(16)(23)(21)(29)+105.1%
Other income (expense)1010033(5)+305.7%
Pretax income2(18)(19)(140)(16)(19)(18)(34)+114.5%
Income tax010(6)0000+29.5%
Net income2(18)(20)(134)(16)(20)(18)(34)+112.4%
Diluted EPS ($)0.03(0.31)(0.34)—(0.28)(0.34)(0.32)—+110.7%
Diluted shares (millions)615958—575757——

Fourth quarters are the fiscal year less the first nine months when the filer reports no discrete fourth quarter, and are marked. Diluted EPS is never derived, so a derived quarter shows none. Italic figures are derived.

Balance sheet

Last eight quarters, newest first, through Q3 FY2026 filed October 28, 2026.

Glaukos Corporation balance sheet, quarterly
Millions of dollarsQ3 FY2026ended Sep 30, 2026filed Oct 28, 2026Q2 FY2026ended Jun 30, 2026filed Jul 29, 2026Q1 FY2026ended Mar 31, 2026filed Apr 30, 2026Q4 FY2025ended Dec 31, 2025filed Feb 23, 2026Q3 FY2025ended Sep 30, 2025filed Oct 31, 2025Q2 FY2025ended Jun 30, 2025filed Aug 4, 2025Q1 FY2025ended Mar 31, 2025filed May 1, 2025Q4 FY2024ended Dec 31, 2024filed Feb 25, 2025YoYQ3 FY2026vs Q3 FY2025
Cash and equivalents1621141049198101114170+65.2%
Short-term investments—————————
Total current assets580516486475455436445450+27.5%
Total assets980921893893999987966975−2.0%
Total current liabilities1271028910188796975+44.8%
Long-term debt—————————
Total liabilities262238222237230222202208+14.1%
Stockholders’ equity717682671656770765764767−6.8%
Shares outstanding (millions)5959595857575757—

Positions at each period end. Nothing on this statement is derived. Long-term debt is the filed noncurrent line only; no total-debt composite is constructed across filers. Italic figures are derived.

Cash flow statement

Last eight quarters, newest first, through Q3 FY2026 filed October 28, 2026.

Glaukos Corporation cash flow statement, quarterly
Millions of dollarsQ3 FY2026ended Sep 30, 2026filed Oct 28, 2026Q2 FY2026ended Jun 30, 2026filed Jul 29, 2026Q1 FY2026ended Mar 31, 2026filed Apr 30, 2026Q4 FY2025ended Dec 31, 2025filed Feb 23, 2026Q3 FY2025ended Sep 30, 2025filed Oct 31, 2025Q2 FY2025ended Jun 30, 2025filed Aug 4, 2025Q1 FY2025ended Mar 31, 2025filed May 1, 2025Q4 FY2024ended Dec 31, 2024filed Feb 25, 2025YoYQ3 FY2026vs Q3 FY2025
Operating cash flow3915(13)7(10)7(19)1+482.3%
Capital expenditures23432122+27.2%
Free cash flow (CFO − capex)3612(16)4(12)6(20)(1)+411.2%
Depreciation and amortization9912129989−2.0%
Share repurchases—————————
Dividends paid—————————

10-Qs file cash flows as year-to-date totals, so quarterly figures are differenced from consecutive filings and marked. Free cash flow is operating cash flow less capital expenditures, computed from the two filed lines. Italic figures are derived.

Annual statements

Every fiscal year filed, newest first, through FY2025 filed February 23, 2026.

Income statement

Glaukos Corporation income statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 23, 2026FY2024ended Dec 31, 2024filed Feb 25, 2025FY2023ended Dec 31, 2023filed Feb 23, 2024FY2022ended Dec 31, 2022filed Feb 24, 2023FY2021ended Dec 31, 2021filed Feb 28, 2022FY2020ended Dec 31, 2020filed Mar 1, 2021FY2019ended Dec 31, 2019filed Mar 2, 2020FY2018ended Dec 31, 2018filed Feb 28, 2019FY2017ended Dec 31, 2017filed Feb 28, 2018FY2016ended Dec 31, 2016filed Mar 15, 2017FY2015ended Dec 31, 2015filed Mar 15, 2016FY2014ended Dec 31, 2014filed Aug 13, 2015FY2013ended Dec 31, 2013filed Aug 13, 2015
Revenue507383315283294225237181159114724621
Cost of revenue112947669679239252116———
Gross profit28328923921422713319815613898593418
Research and development———————503929251916
Selling, general and administrative3322612241931791711771209665442817
Operating income(200)(122)(129)(82)(33)(124)(50)(13)(2)4(10)(13)(14)
Other income (expense)7(23)(5)(16)(16)(9)0120(28)(1)0
Pretax income(193)(146)(134)(98)(49)(132)(50)(12)05(38)(14)(14)
Income tax(5)1110(12)(65)100000
Net income(188)(146)(135)(99)(50)(120)15(13)05(37)(12)(13)
Diluted EPS ($)(3.28)(2.77)(2.78)(2.09)(1.07)(2.70)0.37(0.37)0.000.12(2.13)(5.29)—
Diluted shares (millions)57534847464441353436172,294*—

Balance sheet

Glaukos Corporation balance sheet, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 23, 2026FY2024ended Dec 31, 2024filed Feb 25, 2025FY2023ended Dec 31, 2023filed Feb 23, 2024FY2022ended Dec 31, 2022filed Feb 24, 2023FY2021ended Dec 31, 2021filed Feb 28, 2022FY2020ended Dec 31, 2020filed Mar 1, 2021FY2019ended Dec 31, 2019filed Mar 2, 2020FY2018ended Dec 31, 2018filed Feb 28, 2019FY2017ended Dec 31, 2017filed Feb 28, 2018FY2016ended Dec 31, 2016filed Mar 15, 2017FY2015ended Dec 31, 2015filed Mar 15, 2016FY2014ended Dec 31, 2014filed Aug 13, 2015FY2013ended Dec 31, 2013filed Aug 13, 2015
Cash and equivalents91170931201019762302562227
Short-term investments—————————————
Total current assets47545039544448646926317714912010411—
Total assets8939759401,0021,0501,00681820716613411726—
Total current liabilities1017574726350583027172020—
Long-term debt——————————19—
Total liabilities2372084794724633381453328172130—
Stockholders’ equity65676746253058766767317413811795(151)—
Shares outstanding (millions)5857494847464436353432——

Cash flow statement

Glaukos Corporation cash flow statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 23, 2026FY2024ended Dec 31, 2024filed Feb 25, 2025FY2023ended Dec 31, 2023filed Feb 23, 2024FY2022ended Dec 31, 2022filed Feb 24, 2023FY2021ended Dec 31, 2021filed Feb 28, 2022FY2020ended Dec 31, 2020filed Mar 1, 2021FY2019ended Dec 31, 2019filed Mar 2, 2020FY2018ended Dec 31, 2018filed Feb 28, 2019FY2017ended Dec 31, 2017filed Feb 28, 2018FY2016ended Dec 31, 2016filed Mar 15, 2017FY2015ended Dec 31, 2015filed Mar 15, 2016FY2014ended Dec 31, 2014filed Aug 13, 2015FY2013ended Dec 31, 2013filed Aug 13, 2015
Operating cash flow(15)(61)(58)(33)25(23)0192612(2)——
Capital expenditures86203048751066111
Free cash flow (CFO − capex)(22)(68)(78)(63)(23)(30)(5)9206(3)——
Depreciation and amortization3836343230296655441
Share repurchases————————————0
Dividends paid—————————————

Insider activity

Form 4 filings by officers, directors and 10% owners, November 9, 2024 to November 9, 2026. Only open-market purchases and sales count as buys and sells; awards, exercises, tax withholding and gifts are listed in grey and never counted.

Bought, three months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, three months
$26M
25 sales by 3 insiders; officers and directors $26M
Bought, twelve months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, twelve months
$81M
66 sales by 8 insiders; officers and directors $81M

The last 25 transactions

TradedInsiderRoleTransactionSharesPriceValueHeld afterFiled
Nov 4, 2026Kliman Gilbert HDirectoroption exercise2,500$25.77$64K39,906Nov 5, 2026
Nov 4, 2026Kliman Gilbert HDirectoropen-market sale2,500$253.00$633K37,406Nov 5, 2026
Oct 30, 2026Weisner Aimee SDirectorgift2,382$0.00—15,801Nov 3, 2026
Oct 30, 2026Weisner Aimee SDirectorgiftindirect2,382$0.00—31,887Nov 3, 2026
Oct 30, 2026Navratil TomasCHIEF DEVELOPMENT OFFICERoption exercise4,181$55.00$230K72,976Nov 3, 2026
Oct 30, 2026Navratil TomasCHIEF DEVELOPMENT OFFICERoption exercise8,788$85.94$755K81,764Nov 3, 2026
Oct 30, 2026Navratil TomasCHIEF DEVELOPMENT OFFICERopen-market sale10,221$237.54$2M71,543Nov 3, 2026
Oct 30, 2026Navratil TomasCHIEF DEVELOPMENT OFFICERopen-market sale12,836$238.56$3M58,707Nov 3, 2026
Oct 30, 2026Navratil TomasCHIEF DEVELOPMENT OFFICERopen-market sale14,943$239.64$4M43,764Nov 3, 2026
Oct 30, 2026Navratil TomasCHIEF DEVELOPMENT OFFICERopen-market sale6,436$240.52$2M37,328Nov 3, 2026
Oct 5, 2026Navratil TomasCHIEF DEVELOPMENT OFFICERopen-market sale10b5-1888$163.93$146K69,930Oct 7, 2026
Oct 5, 2026Navratil TomasCHIEF DEVELOPMENT OFFICERopen-market sale10b5-1327$164.78$54K69,603Oct 7, 2026
Oct 5, 2026Navratil TomasCHIEF DEVELOPMENT OFFICERopen-market sale10b5-1312$165.60$52K69,291Oct 7, 2026
Sep 25, 2026Navratil TomasCHIEF DEVELOPMENT OFFICERopen-market sale10b5-1167$151.70$25K72,266Sep 28, 2026
Sep 25, 2026Navratil TomasCHIEF DEVELOPMENT OFFICERopen-market sale10b5-1136$152.71$21K72,130Sep 28, 2026
Sep 25, 2026Navratil TomasCHIEF DEVELOPMENT OFFICERopen-market sale10b5-1229$154.24$35K71,901Sep 28, 2026
Sep 25, 2026Navratil TomasCHIEF DEVELOPMENT OFFICERopen-market sale10b5-11,083$154.88$168K70,818Sep 28, 2026
Sep 16, 2026Navratil TomasCHIEF DEVELOPMENT OFFICERopen-market sale10b5-1103$163.20$17K73,787Sep 18, 2026
Sep 16, 2026Navratil TomasCHIEF DEVELOPMENT OFFICERopen-market sale10b5-1345$164.60$57K73,442Sep 18, 2026
Sep 16, 2026Navratil TomasCHIEF DEVELOPMENT OFFICERopen-market sale10b5-1191$166.20$32K73,251Sep 18, 2026
Sep 16, 2026Navratil TomasCHIEF DEVELOPMENT OFFICERopen-market sale10b5-1460$167.32$77K72,791Sep 18, 2026
Sep 16, 2026Navratil TomasCHIEF DEVELOPMENT OFFICERopen-market sale10b5-1120$168.38$20K72,671Sep 18, 2026
Sep 16, 2026Navratil TomasCHIEF DEVELOPMENT OFFICERopen-market sale10b5-1234$170.95$40K72,437Sep 18, 2026
Sep 16, 2026Navratil TomasCHIEF DEVELOPMENT OFFICERopen-market sale10b5-14$172.00$68872,433Sep 18, 2026
Aug 28, 2026Navratil TomasCHIEF DEVELOPMENT OFFICERopen-market sale7,643$180.25$1M79,991Sep 1, 2026

Full insider history for Glaukos Corporation, or insider activity across all companies. A record of filings, not a recommendation.

Sources

Fiscal year ends in month 12; periods are labeled with the issuer's own fiscal calendar. Values are as most recently filed (restatements apply; per-share values are on current split basis per the connector's split table, flagged in adjusted). Flow items flagged in `derived` were computed (Q4 = FY − nine months; quarterly cash flow differenced from year-to-date filings) rather than read from a filing. `reconciliation.repaired` lists periods where a full-year figure was filed in a quarter slot: that row was dropped and the quarter rebuilt from the annual figure. `reconciliation.quarantined` lists periods where four filed quarters do not sum to the filed year — those quarterly values are withheld, so a blank there is a withholding rather than an absence of reporting.

Filer
GLAUKOS Corp, CIK 1192448 on EDGAR
Extract generated
November 8, 2026
Withheld
2 line-years whose four quarters do not sum to the filed year: other income FY2015, revenue FY2015
Repaired
none
XBRL concepts behind each line

Income statement

Revenue: RevenueFromContractWithCustomerExcludingAssessedTax, SalesRevenueNet
Cost of revenue: CostOfGoodsAndServicesSold
Gross profit: GrossProfit
Research and development: ResearchAndDevelopmentExpense
Selling, general and administrative: SellingGeneralAndAdministrativeExpense
Operating income: OperatingIncomeLoss
Other income (expense): NonoperatingIncomeExpense, OtherNonoperatingIncomeExpense
Pretax income: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
Income tax: IncomeTaxExpenseBenefit
Net income: NetIncomeLoss
Diluted EPS ($): EarningsPerShareDiluted
Diluted shares (millions): WeightedAverageNumberOfDilutedSharesOutstanding

Balance sheet

Cash and equivalents: CashAndCashEquivalentsAtCarryingValue
Short-term investments: not filed
Total current assets: AssetsCurrent
Total assets: Assets
Total current liabilities: LiabilitiesCurrent
Long-term debt: LongTermDebt, LongTermDebtNoncurrent
Total liabilities: Liabilities
Stockholders’ equity: StockholdersEquity
Shares outstanding (millions): dei:EntityCommonStockSharesOutstanding

Cash flow statement

Operating cash flow: NetCashProvidedByUsedInOperatingActivities
Capital expenditures: PaymentsToAcquirePropertyPlantAndEquipment
Free cash flow (CFO − capex): not filed
Depreciation and amortization: DepreciationDepletionAndAmortization
Share repurchases: PaymentsForRepurchaseOfCommonStock
Dividends paid: not filed

The data

The statements on this page as files, generated November 8, 2026.

JSON file
/data/financials/GKOS.json